TY - JOUR
T1 - Predictors of nonuse of a high-potency statin after an acute coronary syndrome
T2 - Insights from the stabilization of plaques using darapladib-thrombolysis in myocardial infarction 52 (SOLID-TIMI 52) trial
AU - Eisen, Alon
AU - Cannon, Christopher P.
AU - Braunwald, Eugene
AU - Steen, Dylan L.
AU - Zhou, Jing
AU - Goodrich, Erica L.
AU - Im, Kyung Ah
AU - Dalby, Anthony J.
AU - Spinar, Jindrich
AU - Daga, Shruti
AU - Lukas, Mary Ann
AU - O'Donoghue, Michelle L.
N1 - Publisher Copyright:
© 2017 The Authors.
PY - 2017
Y1 - 2017
N2 - Background--High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. Methods and Results--The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as ≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n=12 446), 11 850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14 days), but only 5212 (41.9%) were on a high-potency statin. Selected patient factors associated with nonuse of high-potency statins included age ≥75 years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), renal dysfunction (odds ratio 1.17, 95% CI 1.03-1.32), and heart failure during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3 months after baseline, only 49% of patients had low-density lipoprotein cholesterol < 70 mg/dL. Among the 5490 patients (59%) who were not on a high-potency statin at 3 months, lower low-density lipoprotein cholesterol was a predictor of nonuse of a highpotency statin after a median of 2.3 years (odds ratio 1.15 for 10 mg/dL decrease, 95% CI 1.11-1.19). Conclusion--Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with highpotency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events.
AB - Background--High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. Methods and Results--The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as ≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n=12 446), 11 850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14 days), but only 5212 (41.9%) were on a high-potency statin. Selected patient factors associated with nonuse of high-potency statins included age ≥75 years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), renal dysfunction (odds ratio 1.17, 95% CI 1.03-1.32), and heart failure during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3 months after baseline, only 49% of patients had low-density lipoprotein cholesterol < 70 mg/dL. Among the 5490 patients (59%) who were not on a high-potency statin at 3 months, lower low-density lipoprotein cholesterol was a predictor of nonuse of a highpotency statin after a median of 2.3 years (odds ratio 1.15 for 10 mg/dL decrease, 95% CI 1.11-1.19). Conclusion--Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with highpotency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events.
KW - Acute coronary syndrome
KW - Guideline
KW - Secondary prevention
KW - Statin therapy
UR - http://www.scopus.com/inward/record.url?scp=85009986501&partnerID=8YFLogxK
U2 - 10.1161/JAHA.116.004332
DO - 10.1161/JAHA.116.004332
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28077384
AN - SCOPUS:85009986501
SN - 2047-9980
VL - 6
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 1
M1 - e004332
ER -
